SAN DIEGO, April 28, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that its Chief Scientific Officer, Mark Erlander, Ph.D. will present a corporate overview at the 41st Annual Deutsche Bank Healthcare Conference taking place May 4-5, 2016 at the InterContinental Hotel in Boston, MA.
Trovagene is scheduled to present on Wednesday, May 4, 2016 at 11:20 am EDT. The Company’s recently appointed Chief Executive Officer, Bill Welch, and Dr. Erlander will be available for one-on-one meetings during the conference. The presentation will be webcast live at http://edge.media-server.com/m/p/vy3enttc and can also be accessed through the investor relations web page at www.trovagene.com. A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days.
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.
Contact | |||
Investor Relations | Media Relations | ||
David Moskowitz Vice President, Investor Relations | Jody LoMenzo Corporate Practice Counsel | ||
Trovagene, Inc. | Inventiv Health Public Relations | ||
858-952-7593 | 212-364-0458 | ||
Logo - http://photos.prnewswire.com/prnh/20120620/LA28014LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trovagene-to-present-at-the-41st-annual-deutsche-bank-healthcare-conference-300259085.html
SOURCE Trovagene, Inc.
